Education
About Us
Working with TipRanks
Follow Us
Lonza Group (LZAGY)
OTHER OTC:LZAGY
LZAGY Stock Chart & Stats
$66.71
$0.25(0.41%)
At close: 4:00 PM EST
$66.71
$0.25(0.41%)
Day’s Range― - ―
52-Week Range$56.25 - $73.76
Previous CloseN/A
Volume8.91K
Average Volume (3M)5.62K
Market Cap
$46.14B
Enterprise Value$40.85B
Total Cash (Recent Filing)$719.00M
Total Debt (Recent Filing)$4.18B
Price to Earnings (P/E)43.1
Beta0.69
Next Earnings
Jul 29, 2026EPS Estimate
1.02Next Dividend Ex-DateN/A
Dividend Yield0.63%
Share Statistics
EPS (TTM)1.12
Shares Outstanding702,290,200
10 Day Avg. Volume0
30 Day Avg. Volume5,617
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)4.09
Price to Sales (P/S)5.98
P/FCF Ratio-191.57
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue6.55
Enterprise Value/Gross Profit18.13
Enterprise Value/Ebitda31.19
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CDMO Revenue Growth And Contracting VisibilitySustained, high single‑ to double‑digit CDMO growth and a commercial contracting pipeline above CHF 10bn provide multi‑year revenue visibility. Long-term contracts and Vacaville integration deepen customer ties, reducing demand cyclicality and supporting durable top‑line expansion.
Margin Expansion And High‑margin PlatformsImproving CORE EBITDA margins, driven by scale and high‑profit platforms (ADS >40% margins), indicate sustainable operational leverage. If maintained, higher margins support stronger cash generation and reinvestment capacity, enhancing competitive positioning in outsourced biologics and synthesis.
Robust Balance Sheet And Improving Cash GenerationA solid equity base and moderate leverage give Lonza financial flexibility to fund growth projects and absorb shocks. Combined with material FCF improvement in 2025, this supports disciplined capital allocation, continued investment in capacity, and resilience through biotech cycle variability.
Bears Say
CapEx Intensity And Negative Free Cash Flow PressureHeavy capex for 23 growth projects and elevated CDMO spending (CHF 1.3bn in 2025) has driven negative free cash flow historically. Persistently high investment needs can constrain distributable cash, increase financing reliance, and delay realization of returns from new capacity.
Operational Issues In Specialized Modalities (Cell & Gene)Execution reliability in specialized modalities is critical for CDMO reputation and contract retention. Site operational failures in Cell & Gene highlight execution risk that can disrupt customer timelines, delay revenue recognition, and weaken long‑term trust in high‑value, capacity‑constrained services.
Inconsistent Revenue Trends And Rising LiabilitiesDespite a strong 2025, revenue growth has been uneven and net income lags prior peaks, while total liabilities have increased. Persistent inconsistency and higher liabilities could pressure margins and ROE over time, reducing financial flexibility and complicating capital allocation choices.
Lonza Group News
LZAGY FAQ
What was Lonza Group’s price range in the past 12 months?
Lonza Group lowest stock price was $56.25 and its highest was $73.76 in the past 12 months.
What is Lonza Group’s market cap?
Lonza Group’s market cap is $46.14B.
When is Lonza Group’s upcoming earnings report date?
Lonza Group’s upcoming earnings report date is Jul 29, 2026 which is in 160 days.
How were Lonza Group’s earnings last quarter?
Lonza Group released its earnings results on Jan 28, 2026. The company reported $1.121 earnings per share for the quarter, missing the consensus estimate of $1.191 by -$0.07.
Is Lonza Group overvalued?
According to Wall Street analysts Lonza Group’s price is currently Overvalued.
Does Lonza Group pay dividends?
Lonza Group pays a Annually dividend of $0.421 which represents an annual dividend yield of 0.63%. See more information on Lonza Group dividends here
What is Lonza Group’s EPS estimate?
Lonza Group’s EPS estimate is 1.02.
How many shares outstanding does Lonza Group have?
Lonza Group has 702,290,200 shares outstanding.
What happened to Lonza Group’s price movement after its last earnings report?
Lonza Group reported an EPS of $1.121 in its last earnings report, missing expectations of $1.191. Following the earnings report the stock price went down -2.262%.
Which hedge fund is a major shareholder of Lonza Group?
Currently, no hedge funds are holding shares in LZAGY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lonza Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
LZAGY Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.1K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.51%
12-Months-Change
Fundamentals
Return on Equity
7.97%
Trailing 12-Months
Asset Growth
18.69%
Trailing 12-Months
Company Description
Lonza Group
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.
LZAGY Company Deck
LZAGY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong operational and financial performance for FY2025 with robust revenue growth (+21.7% ccy), margin expansion (CORE EBITDA 31.6%, +1.4pp) and material free cash flow improvement. Management provided clear evidence of successful Vacaville integration, high contracting activity, and an optimistic 2026 outlook (11%–12% ccy growth and margin above 32%). Key challenges include softness in Specialized Modalities (notably Cell & Gene operational issues), mix-related dilution in Integrated Biologics, FX headwinds and continued high but normalizing CapEx and working capital requirements. On balance, the positive metrics, guidance upgrade to earlier-than-expected margin corridor, strong cash generation and successful integration evidence significantly outweigh the operational and market risks noted.View all LZAGY earnings summariesLZAGY Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
―
Insiders
0.04% Mutual Funds
0.02% Other Institutional Investors
99.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---